Intercept Pharmaceuticals (DB:I4P) - Hisse Senedi Fiyatı, Haberler ve Analizler

I4P Stoklara Genel Bakış

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.

Şirket hakkında

I4P temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 56.2% daha düşük bir oranda işlem görüyor

Kazançların yılda 42.37% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 22.4% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Intercept Pharmaceuticals, Inc. Rakipler

Formycon

XTRA:FYB

€821.0m

Biotest

XTRA:BIO3

€1.4b

MorphoSys

HMSE:MOR

€2.6b

Heidelberg Pharma

XTRA:HPHA

€116.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Intercept Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$17.52
52 Haftanın En Yüksek Seviyesi	US$19.97
52 Haftanın En Düşük Seviyesi	US$8.16
Beta	0.88
11 Aylık Değişim	0.46%
3 Aylık Değişim	90.52%
1 Yıllık Değişim	14.92%
33 Yıllık Değişim	-45.23%
5 Yıllık Değişim	-79.17%
Halka arzdan bu yana değişim	17.29%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	I4P	DE Biotechs	DE Pazar
7D	-0.8%	-3.1%	-1.0%
1Y	14.9%	-15.2%	16.1%

Getiri vs. Endüstri: I4P geçen yıl % -15.2 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: I4P geçen yıl % 16.1 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is I4P's price volatile compared to industry and market?
I4P volatility
I4P Average Weekly Movement	22.8%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

İstikrarlı Hisse Senedi Fiyatı: I4P hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: I4P 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 15% dan 23% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2002	341	Jerry Durso	www.interceptpharma.com

Intercept Pharmaceuticals, Inc. Temel Bilgiler Özeti

Intercept Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
I4P temel i̇stati̇sti̇kler
Piyasa değeri	€742.08m
Kazançlar(TTM)	-€53.66m
Gelir(TTM)	€296.65m

2.5x

P/S Oranı

-13.8x

F/K Oranı

I4P aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
I4P gelir tablosu (TTM)
Gelir	US$317.68m
Gelir Maliyeti	US$632.00k
Brüt Kâr	US$317.05m
Diğer Giderler	US$374.52m
Kazançlar	-US$57.47m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.37
Brüt Marj	99.80%
Net Kâr Marjı	-18.09%
Borç/Özkaynak Oranı	311.6%

I4P uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

I4P Stoklara Genel Bakış

Ödüller

Risk Analizi

Intercept Pharmaceuticals, Inc. Rakipler

XTRA:FYB

€821.0m

XTRA:BIO3

€1.4b

HMSE:MOR

€2.6b

XTRA:HPHA

€116.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Recent updates

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings released: US$0.066 loss per share (vs US$3.04 loss in 3Q 2022)

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.68 loss in 2Q 2022)

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$0.77 loss per share (vs US$1.13 loss in 1Q 2022)

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast to breakeven in 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast to breakeven in 2024

Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings released: US$0.58 loss per share (vs US$1.22 loss in 1Q 2021)

Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Intercept Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Pomerantz Law Firm Announces the Filing of A Class Action Against Intercept Pharmaceuticals, Inc

Forecast to breakeven in 2024

Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH

Intercept Pharmaceuticals, Inc. Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$2.02 loss in 3Q 2020)

Intercept Pharmaceuticals, Inc. announced a financing transaction

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$1.92 loss in 2Q 2020)

Intercept Pharmaceuticals, Inc. to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021

Independent Director Daniel Welch has left the company

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2021

First quarter 2021 earnings released: US$1.22 loss per share (vs US$2.86 loss in 1Q 2020)

CFO, Treasurer & Principal Accounting Officer has left the company

Intercept Pharmaceuticals, Inc. Appoints Rocco Venezia as Chief Accounting Officer